Cidara Therapeutics Inc (NASDAQ: CDTX) stock closed at $88.58 on 9/24/25 after a major increase of 20.5%. Moreover, trading volume in this advance was exceptionally high at 542% of normal. The stock has been exceptionally strong relative to the market over the last nine months and has risen 36.9% during the last week.
Current PriceTarget Research Rating
Cidara Therapeutics has a current Value Trend Rating of C (Neutral). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Cidara Therapeutics has a very low Appreciation Score of 10 but a very high Power Rating of 92, resulting in the Neutral Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment